Janux Therapeutics, Inc. 8-K

What Happened Janux Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders held June 11, 2026 (record date April 17, 2026). Of 60,961,546 shares outstanding, 53,744,922 shares were present virtually or by proxy. Stockholders elected two Class II directors — Natasha Hernday and Eric Dobmeier — each to serve until the 2029 Annual Meeting. The company also ratified Ernst & Young LLP as its independent registered public accounting firm for fiscal 2026 and approved, on an advisory (non‑binding) basis, the compensation of its named executive officers.

Key Details

• Record date: April 17, 2026; outstanding shares entitled to vote: 60,961,546; shares present/represented: 53,744,922.
• Director election votes:
  • Natasha Hernday — For: 42,850,103; Withheld: 4,519,796; Broker non‑votes: 6,375,023.
  • Eric Dobmeier — For: 46,279,387; Withheld: 1,090,512; Broker non‑votes: 6,375,023.
• Auditor ratification (Ernst & Young LLP): For 53,560,969; Against 113,446; Abstentions 70,507.
• Advisory vote on executive compensation: For 42,749,182; Against 4,574,376; Abstentions 46,341; Broker non‑votes 6,375,023.

Why It Matters These outcomes confirm board composition and governance continuity through 2029 for the elected directors and preserve the company’s auditor relationship for 2026, both of which affect oversight of Janux’s financial reporting and strategy. The advisory approval of executive compensation indicates majority shareholder support for pay practices, though it is non‑binding. Investors should note the level of broker non‑votes, which reflect shares present without voting instructions and can affect the margin on certain proposals.